NORTHSTAR ASSET MANAGEMENT Co Sells 650 Shares of Johnson & Johnson $JNJ

NORTHSTAR ASSET MANAGEMENT Co cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,376 shares of the company’s stock after selling 650 shares during the quarter. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Johnson & Johnson were worth $3,112,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Greenup Street Wealth Management LLC lifted its position in Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after buying an additional 60 shares during the period. Ellis Investment Partners LLC boosted its holdings in Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after acquiring an additional 62 shares in the last quarter. Cypress Wealth Services LLC grew its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after acquiring an additional 62 shares during the last quarter. Horizon Bancorp Inc. IN raised its position in shares of Johnson & Johnson by 11.2% in the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after purchasing an additional 64 shares during the last quarter. Finally, Global Strategic Investment Solutions LLC boosted its stake in Johnson & Johnson by 3.5% in the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after purchasing an additional 65 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 1.1%

NYSE:JNJ opened at $190.38 on Friday. The business has a fifty day moving average price of $182.26 and a 200-day moving average price of $166.13. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.76. The firm has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. Bank of America upped their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Loop Capital set a $190.00 price objective on Johnson & Johnson in a research report on Wednesday. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.